{"title":"卵巢功能抑制:现在是过早行动的好时机吗?","authors":"S. Jandyal, J. Bajpai","doi":"10.4172/2329-6771.1000183","DOIUrl":null,"url":null,"abstract":"Ovarian function suppression (OFS) an old endocrine therapy has been tested in premenopausal women with early breast cancer (EBC) but not widely accepted in modern practice. The question is re-addressed in recent big trials, however the big dilemma doesn't resolved. This perspective touch upon the ancient as well as current evidence of OFS in these young early breast cancer women and try to enlighten the readers further on this controversial topic wherein there is lots of light but little illumination.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"82 1","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ovarian Function Suppression: Is it the Right Time to Jump the Gun?\",\"authors\":\"S. Jandyal, J. Bajpai\",\"doi\":\"10.4172/2329-6771.1000183\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ovarian function suppression (OFS) an old endocrine therapy has been tested in premenopausal women with early breast cancer (EBC) but not widely accepted in modern practice. The question is re-addressed in recent big trials, however the big dilemma doesn't resolved. This perspective touch upon the ancient as well as current evidence of OFS in these young early breast cancer women and try to enlighten the readers further on this controversial topic wherein there is lots of light but little illumination.\",\"PeriodicalId\":16252,\"journal\":{\"name\":\"Journal of Integrative Oncology\",\"volume\":\"82 1\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Integrative Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2329-6771.1000183\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Integrative Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-6771.1000183","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ovarian Function Suppression: Is it the Right Time to Jump the Gun?
Ovarian function suppression (OFS) an old endocrine therapy has been tested in premenopausal women with early breast cancer (EBC) but not widely accepted in modern practice. The question is re-addressed in recent big trials, however the big dilemma doesn't resolved. This perspective touch upon the ancient as well as current evidence of OFS in these young early breast cancer women and try to enlighten the readers further on this controversial topic wherein there is lots of light but little illumination.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
